Gamida Cell Ltd.

We’re excited to announce that Gamida Cell will be adding APHEXDA® (motixafortide) to our commercial portfolio to strengthen our capabilities in advancing options for patients in need of stem cell transplants.    With APHEXDA® joining Gamida Cell's portfolio alongside OMISIRGE® (omidubicel-onlv) – the first FDA-approved, NAM-modified cell therapy – we’re able to enhance support for patients throughout their stem cell transplant journey.   https://lnkd.in/dsgTcKgP #GamidaCell #Ayrmid #Omisirge #APHEXDA #CellTherapy #Oncology #HealthcareInnovation #Hematology See Full Prescribing Information for OMISIRGE®, including Boxed Warning, here: https://lnkd.in/dEds7Ecg See Full Prescribing Information for APHEXDA®, here: https://lnkd.in/dqsQiSjc

Mark your calendars! See what’s new with Gamida at this year’s NMDP One Forum and ASTCT Toxicities Conference.

Today, Gamida Cell announced it has commenced a restructuring process supported by Highbridge Capital Management, the company’s principal lender. This transaction is anticipated to provide the long-term financial runway needed to support ongoing commercialization of our FDA-approved cell therapy. “This restructuring transaction will enable Gamida Cell to remain a going concern and will support our ongoing efforts to make our FDA approved cell therapy product available to more transplant centers and their patients,” said Abbey Jenkins, President and CEO of Gamida Cell. Learn more in our press release: https://lnkd.in/ev5Rymmg

March marks Women’s History Month, and March 8th marks International Women’s Day. This year’s theme for International Women's Day is #InspireInclusion, which represents building a more inclusive future where women are more than just present – but a part of the conversation, valued and empowered.     This month, and throughout the year, let’s celebrate the achievements of women both past and present and continue to inspire inclusivity throughout the world.    #IWD2024 #WomenInStem 

Michele Korfin, Chief Operating and Chief Commercial Officer at Gamida Cell, recently spoke with Newsweek’s Investment Reports about the importance of cell therapy as an option for patients with cancer, and the efforts to broaden access to allogeneic stem cell transplant.   To read the full article, visit: https://lnkd.in/gwJeeAQg     Note: Gamida Cell is not responsible for and does not endorse the content found within third party websites.    #celltherapy #biotech 

On Employee Appreciation Day, Gamida Cell recognizes each and every one of our employees for their hard work and dedication.     To all of our employees, thank you for everything you do.     #EmployeeAppreciationDay #CellTherapy #Biotech 

The NMDP Registry® is the world’s largest registry of stem cell transplant donors, with over 19 million potential donors and over 249,000 cord blood units (CBUs). Despite this, according to Gamida Cell market research, approximately 1,700 patients in the U.S. are unable to find a donor each year, with patients from diverse racial and ethnic backgrounds being most impacted. According to NMDP, patients who identify as Black or African American have a 29% chance of finding a match, compared with patients who identify as Asian or Pacific Islander (47%), Hispanic or Latino (48%), Native American (60%) and white (79%). According to U.S. Census data, the U.S. population is more racially and ethnically diverse than it has ever been previously. With a greater variety of HLA types, a key piece of genetic DNA needed for matching, it’s harder to find a closely matched donor. Increasing the diversity in the donor registry is key to addressing the equity gap between those who have access to a stem cell transplant and those who need one. Learn more about how a patient’s ethnic background affects donor matching here: https://lnkd.in/eBMgGEmS #healthequity #NMDP #SavingLives

Today, two posters highlighting Gamida Cell research were presented at #Tandem24, Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). Mitchell E. Horwitz, MD, Stem Cell Transplant Specialist and Professor of Medicine at Duke Cancer Institute presented data from an Expanded Access Program (EAP) evaluating outcomes in patients with hematologic malignancies following allogeneic stem cell transplant with omidubicel-onlv. Brian C. Shaffer, Associate Professor of Medicine and Head of the Adult Mismatched Donor Sub-Program at Memorial Sloan Kettering Cancer Center in New York presented data from the Phase I study of allogeneic cryopreserved natural killer (NK) cell therapy candidate GDA-201 in patients with CD20 positive non-Hodgkin lymphoma. Learn more about the poster presentations in our press release: https://lnkd.in/euzmjQMm #celltherapy #ASTCT #CIBMTR

Learn more about OMISIRGE® (omidubicel-onlv) at ASTCT On February 21, 1:30-2:30pm CT Dr. Ronit Simantov, Gamida Cell Chief Medical & Scientific Officer will present “Latest Advancements in Allo-HCT” WARNING: INFUSION REACTIONS, GRAFT VERSUS HOST DISEASE, ENGRAFTMENT SYNDROME, and GRAFT FAILURE. See Full Prescribing Information, including Boxed Warning, at https://lnkd.in/etxVyNF2 or visit Omisirge.com

The Tandem Meetings are coming up on February 21-25! Visit Gamida Cell at Booth #604 to learn more about OMISIRGE® (omidubicel-onlv). See full Prescribing Information, including Boxed Warning, here: https://lnkd.in/etxVyNF2